|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 March 2001, Vol. 97, No. 5, pp. 1508-1510
BRIEF REPORT
Sperm protein 17 is a novel cancer-testis antigen in
multiple myeloma
Seah H. Lim,
Zhiqing Wang,
Maurizio Chiriva-Internati, and
Yuying Xue
From the Center for Immunology and Microbial Disease
and the Department of Medicine, Albany Medical College, Albany, NY.
Various studies have demonstrated the aberrant expression of normal
testicular proteins in neoplastic cells. These proteins collectively
form the new class of tumor antigens called cancer-testis (CT)
antigens. Their selective normal tissue expression makes them ideal
antigens for immune targeting of the malignant disease. In this study,
the expression of a spermatozoa protein, Sp17, in multiple myeloma was
investigated. It was found that Sp17 is detectable in tumor
cells from 12 of 47 (26%) myeloma patients. Reverse
transcription polymerase chain reaction (RT-PCR) and Western blot
analysis detected Sp17 transcripts and proteins, respectively. Northern
blot analysis and RT-PCR demonstrated that Sp17 transcripts were
detected only in normal testis, supporting its tissue specificity. Since a high proportion of normal individuals develop antibodies against Sp17 following vasectomy, Sp17 is likely to be a highly immunogenic protein in vivo. Sp17 is therefore a novel member of the CT
antigen family and should be an ideal target for immunotherapy of
multiple myeloma.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Hayashi, Y. Matsuzaki, G. Hasegawa, T. Yaguchi, S. Kurihara, T. Fujita, T. Kageshita, M. Sano, and Y. Kawakami
Identification of a Novel Cancer-Testis Antigen CRT2 Frequently Expressed in Various Cancers Using Representational Differential Analysis
Clin. Cancer Res.,
November 1, 2007;
13(21):
6267 - 6274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Azuma, T. Otsuki, K. Kuzushima, C. J. Froelich, S. Fujita, and M. Yasukawa
Myeloma Cells Are Highly Sensitive to the Granule Exocytosis Pathway Mediated by WT1-Specific Cytotoxic T Lymphocytes
Clin. Cancer Res.,
November 1, 2004;
10(21):
7402 - 7412.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Wang, Y. Zhang, A. Mandal, J. Zhang, F. J. Giles, J. C. Herr, and S. H. Lim
The Spermatozoa Protein, SLLP1, Is a Novel Cancer-Testis Antigen in Hematologic Malignancies
Clin. Cancer Res.,
October 1, 2004;
10(19):
6544 - 6550.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chiriva-Internati, F. Grizzi, B. Franceschini, P. L. Hermonat, R. K. Bright, K. Bumm, N. Dioguardi, and W. M. Kast
Is sperm protein 17 a useful target for tumor immunotherapy?
Blood,
September 15, 2003;
102(6):
2308 - 2309.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grizzi, M. Chiriva-Internati, B. Franceschini, P. L. Hermonat, G. Soda, S. H. Lim, and N. Dioguardi
Immunolocalization of Sperm Protein 17 in Human Testis and Ejaculated Spermatozoa
J. Histochem. Cytochem.,
September 1, 2003;
51(9):
1245 - 1248.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Wei and S Juneja
Bone marrow immunohistology of plasma cell neoplasms
J. Clin. Pathol.,
June 1, 2003;
56(6):
406 - 411.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Wang, Y. Zhang, H. Liu, E. Salati, M. Chiriva-Internati, and S. H. Lim
Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies
Blood,
February 1, 2003;
101(3):
955 - 960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Chiriva-Internati, Z. Wang, E. Salati, K. Bumm, B. Barlogie, and S. H. Lim
Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma
Blood,
July 18, 2002;
100(3):
961 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Grizzi, S. H. Lim, M. Chiriva-Internati, B. Franceschini, Z. Wang, D. Lawrence, N. Dioguardi ;, R. D. Sanderson, and H. M. Lacy
Sperm protein 17 is not expressed on normal leukocytes
Blood,
May 1, 2002;
99(9):
3479 - 3481.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Lacy and R. D. Sanderson
Sperm protein 17 is expressed on normal and malignant lymphocytes and promotes heparan sulfate-mediated cell-cell adhesion
Blood,
October 1, 2001;
98(7):
2160 - 2165.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gorschluter, C. Ziske, A. Glasmacher, and I. G. H. Schmidt-Wolf
Current Clinical and Laboratory Strategies to Augment the Efficacy of Immunotherapy in Multiple Myeloma
Clin. Cancer Res.,
August 1, 2001;
7(8):
2195 - 2204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
